论文部分内容阅读
AIM:To compare the therapeutic effect of transcatheterarterial chemoembolization (TACE),laparoscopic radiofrequencyablation (LRFA),and conservative treatment for the therapyof decompensated liver cirrhosis patients with hepatocellularcarcinomas (HCC).METHODS:Between October 2000 and July 2003,onehundred patients with histologically proven primary HCC andclinical decompensated liver cirrhosis (Child classification Bor C) were included in this study.Forty patients receivedLRFA (LRFA group),twenty received TACE (TACE group),and forty received conservative treatment (control group).We compared the survival,recurrence,and complication ratesin these three groups,making adjustment using the tumormetastastic node staging system.RESULTS:The major complication rate in the TACE group(9/20) was significantly higher than that in the LRFA group(7/40).For patients with TMN stage Ⅱ HCC,the survivalrate of the LRFA group was better than that of the TACEand control groups (P=0.003) but the recurrence ratesbefween the LRFA and TACE groups did not differ.CONCLUSION:The LRFA group of patients had betterclinical outcomes in terms of survival and complication ratesin comparison with the TACE group or conservative treatmentin patients with decompensated liver cirrhosis,especially inTMN patients with stage Ⅱ HCC.LRFA is thus an appropriatealternative treatment for poor liver function among patientswith HCC.
AIM: To compare the therapeutic effect of transcatheter arterial chemoembolization (TACE), laparoscopic radiofrequency ablation (LRFA), and conservative treatment for the therapy of decompensated liver cirrhosis patients with hepatocellular carcinoma (HCC). METHODS: Between October 2000 and July 2003, onehundred patients with histologically proven Primary HCC and clinically decompensated liver cirrhosis (Child classification Bor C) were included in this study. Forty patients received LRF group (LRFA group), twenty received TACE (TACE group), and forty received conservative treatment (control group) .We compared the survival, recurrence , and complication rates of these three groups, making adjustment using the tumor metastasis node staging system .RESULTS: The major complication rate in the TACE group (9/20) was significantly higher than that in the LRFA group (7/40) .For patients with TMN stage II HCC, the survival rate of the LRFA group was better than that of the TACE and control groups (P = 0.003) but the recurrence ratesbefween the the LRFA and TACE groups did not differ.CONCLUSION: The LRFA group of patients had betterclinical outcomes in terms of survival and complication ratesin comparison with the TACE group or conservative treatment in patients with decompensated liver cirrhosis, especially in TNM patients with stage II HCC.LRFA therefore thus an appropriate alternative treatment for poor liver function among patients with HCC.